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Aims Inflammation is an important driver of hypertension. Periodontitis is a chronic inflammatory disease, which could
provide a mechanism for pro-hypertensive immune activation, but evidence of a causal relationship in humans is
scarce. We aimed to investigate the nature of the association between periodontitis and hypertension.
...................................................................................................................................................................................................
Methods
and results
We performed a two-sample Mendelian randomization analysis in the 750 000 UK-Biobank/International
Consortium of Blood Pressure-Genome-Wide Association Studies participants using single nucleotide polymor-
phisms (SNPs) in SIGLEC5, DEFA1A3, MTND1P5, and LOC107984137 loci GWAS-linked to periodontitis, to ascer-
tain their effect on blood pressure (BP) estimates. This demonstrated a significant relationship between
periodontitis-linked SNPs and BP phenotypes. We then performed a randomized intervention trial on the effects
of treatment of periodontitis on BP. One hundred and one hypertensive patients with moderate/severe periodon-
titis were randomized to intensive periodontal treatment (IPT; sub- and supragingival scaling/chlorhexidine; n= 50)
or control periodontal treatment (CPT; supragingival scaling; n= 51) with mean ambulatory 24-h (ABPM) systolic
BP (SBP) as primary outcome. Intensive periodontal treatment improved periodontal status at 2 months, compared
to CPT. This was accompanied by a substantial reduction in mean SBP in IPT compared to the CPT (mean
difference of -11.1 mmHg; 95% CI 6.5–15.8; P< 0.001). Systolic BP reduction was correlated to periodontal status
improvement. Diastolic BP and endothelial function (flow-mediated dilatation) were also improved by IPT. These
cardiovascular changes were accompanied by reductions in circulating IFN-c and IL-6 as well as activated (CD38þ)
and immunosenescent (CD57þCD28null) CD8þT cells, previously implicated in hypertension.
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VC The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestrict-
ed reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
European Heart Journal (2019) 0, 1–12 CLINICAL RESEARCH
doi:10.1093/eurheartj/ehz646 Hypertension
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz646/5556904 by U
niversity of G
lasgow
 user on 11 Septem
ber 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
...................................................................................................................................................................................................
Conclusion A causal relationship between periodontitis and BP was observed providing proof of concept for development of
clinical trial in a large cohort of hypertensive patients. ClinicalTrials.gov: NCT02131922.
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Introduction
Hypertension is a common chronic disease impacting 1.4 billion peo-
ple worldwide, accounts for 10.4 million (9.39–11.5) deaths/year.1
Despite the availability of multiple anti-hypertensive agents, 71% of
patients fail to achieve blood pressure (BP) below 130/80 mmHg.2
Whilst this could be partially explained by poor treatment adherence,
persistently elevated BP in these patients, highlights insufficient under-
standing of the mechanisms of hypertension.
Experimental and observational clinical evidence suggests a prom-
inent role of inflammation in the development of hypertension.3 In
particular, activation of immune cells has been demonstrated in
hypertension.4–6 Hypertension is more prevalent in patients with im-
mune-mediated disorders, such as psoriasis, rheumatoid arthritis or
systemic lupus erythematosus.7 Thus, chronic inflammatory disorders,
could provide a substrate for the pro-hypertensive inflammation.
Periodontitis is one of the commonest inflammatory conditions
worldwide, representing the sixth most prevalent condition world-
wide1,8 with prevalence of 20–50%.9 It is linked to cardiovascular in-
flammation and endothelial dysfunction.10 Therefore, if causally
associated, periodontitis could significantly contribute to the global
hypertensive burden and interventions targeting oral inflammation
would have an important role in the prevention of hypertension and
its complications.8,11 Observational evidence suggests that
moderate-severe periodontitis is associated with increased odds for
hypertension.12
Because of this, it is imperative to establish if periodontitis can
cause hypertension. Our group has recently shown that immune acti-
vation induced by a keystone periodontal pathogen (Porphyromonas
gingivalis) promotes the development of hypertension in mice.13
Small interventional studies concluded that intensive periodontal
therapy may lead to BP reduction, although sufficiently powered evi-
dence in well-defined hypertensive cohorts is lacking.12
Therefore, we aimed to investigate the nature of the association
between periodontitis and hypertension using two experimental
approaches: (i) a Mendelian randomization (MR) analysis utilizing gen-
etic, BP data from the UK Biobank, and the International Consortium
of Blood Pressure (ICBP)–Genome-Wide Association Studies
(GWAS) population and (ii) performing a randomized controlled trial
of non-surgical periodontal therapy in hypertensive patients, using
24-h ambulatory BP monitoring as a primary outcome.
Methods
Mendelian randomization
Mendelian randomization is one of the methods that can be used to test
causal relationship between risk factors and various phenotypes including
disease outcomes.14 Growing number of single nucleotide polymor-
phisms (SNPs) that are convincingly associated with certain risk factors
(e.g. smoking habits, blood lipid profile, or presence of periodontitis) in
GWAS allows researchers to use these SNPs as instrumental variables
that approximate lifetime exposure to risk factor and test these SNPs for
an association with a phenotype of interest.14
A two-sample Mendelian randomization analysis was performed to in-
vestigate a causal link between periodontitis and BP. Four SNPs, in
LOC107984137 (rs729876), MTND1P5 (rs16870060), DEFA1A3
(rs2738058), and SIGLEC5 (rs4284742) loci, previously associated with
periodontitis in GWAS,15,16 were used as instrumental variables (IVs) in
Mendelian randomization analysis. These SNPs, therefore, were consid-
ered as a periodontitis exposure proxy, which were then tested in the
context of BP phenotypes. A palindromic rs1537415 SNP in GLT6D1,
associated with periodontitis in GWAS as well,17 was excluded from the
analysis due to high allele frequency as well as due to the lack of proxy
SNPs in Caucasians. GWAS data on BP, performed by Evangelou et al.18
from UK-Biobank and ICBP-GWAS (including 750 000 participants),
were used to extract estimates of association between instrumental vari-
ables and systolic BP and diastolic BP (SBP and DBP) and pulse pressure
(PP). Additional details are provided in Supplementary material online.
Randomized clinical trial
We performed a single-centre, parallel-group, randomized study to as-
sess the effect of intensive non-surgical periodontal treatment (IPT;
whole mouth subgingival and supragingival scaling of the teeth using also
0.2% chlorhexidine gel) compared with conventional care (supragingival
scaling) and a 2-month follow-up. Consecutive patients from general den-
tal practices in Krakow, Poland and from among referrals to the
University Dental Clinic in Krakow. Patients who had previously been
diagnosed with hypertension (in accordance with ESC/ESH diagnostic cri-
teria19 were receiving stable treatment using at least one anti-
hypertensive agent, since at least 6 months, and had an office BP of >140/
90 mmHg at the time of visit (average of at least three resting measure-
ments)20 were enrolled into the study if they also presented with moder-
ate to severe periodontitis (using the Centre for Disease Control–
American Association of Periodontology case definitions).21,22 Exclusion
criteria included acute and major chronic inflammatory/immune disor-
ders including autoimmune conditions, infections (including tuberculosis,
HIV, hepatitis B, and hepatitis C), pulmonary, liver diseases and malignan-
cies (within the last 5 years) as assessed by the examining clinician.
Patients who had received treatment with medications known to affect
periodontal status were also excluded (phenytoin and cyclosporine).
Patients using any form of systemic or local immunosuppression (includ-
ing steroids) within the previous 6 months were excluded, as were
patients with any cause of secondary hypertension.
After identification in general medical practice, all eligible participants
have first screened for office BP as well as full dental examination for in-
clusion into the study. Secondly, the first study visit (baseline) occurred
within 3–14 days from the patient identification visit. At baseline, ambula-
tory 24-h blood pressure monitoring (ABPM), blood samples collection
and vascular function assessment were undertaken. ABPM was removed
2 M. Czesnikiewicz-Guzik et al.
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24-h later in all participants, during the first dental treatment session.
All patients who fulfilled criteria and provided informed consent were
randomized, after run-in period, 1:1 using a computer-generated table to
receive either IPT or CPT. Treatment allocation was concealed in an opa-
que envelope that was opened on the day of treatment by the treating
physician. All other investigators, including cardiovascular physicians, BP
nurses, laboratory staff, and staff involved in data collection and analysis
remained masked to the treatment allocation.
Intensive periodontal treatment consisted of a single session of whole
mouth supragingival and subgingival scaling of the teeth under local anaes-
thesia with the topical application of 0.2% chlorhexidine gel (PerioKin,
UK). CPT consisted of a single session of supragingival scaling of the teeth.
All participants received dental hygiene instructions and were then fol-
lowed up the next day, 7–10 days later, and 2 months after the dental
treatment session. Full dental examination and cardiovascular assess-
ments were repeated 2 months after therapy. At the end of the study,
patients with CPT received subgingival dental scaling as required. Anti-
hypertensive and other medication use by patients was monitored during
each visit. Any change would result in termination of patient’s participa-
tion in the study.
Average systolic 24-h ambulatory BP at 2 months was the prespecified
primary outcome, while vascular function and inflammatory soluble and
cellular biomarkers were secondary endpoints. The study was approved
by the Jagiellonian University Ethics Committee. All participants provided
written informed consent prior to being enrolled into the study. The
study was registered with ClinicalTrials.gov: NCT02131922. Additional
details are provided in Supplementary material online.
Office and 24-h ABPM determination
Office BP was measured using Omron M digital BP monitor by a BP
clinic nurse. Three measurements after resting in a quiet and
temperature-controlled room were performed and average was
recorded. ABPM was performed by Department of Internal Medicine
ABPM lab using Spacelabs Ultralite 90217 devices in accordance with
manufacturer recommendations and in agreement with current ESC/ESH
Guidelines.20
Vascular function assessment
Flow-mediated dilatation (FMD) of the brachial artery was used to deter-
mine the vascular endothelial function and nitroglycerine-mediated dilata-
tion was used for measuring endothelial-independent vasodilatation.
Analysis was performed using Vascular Tools 5 software by two inde-
pendent vascular technicians masked to the treatment allocation and as
previously described.23,24
Flow cytometric analysis
A panel of circulating blood cell features was performed as previously
described.5,6,23,25 Additional details are provided in Supplementary ma-
terial online.
Plasma cytokine measurements
Blood samples were centrifuged at 400g for 10 min. Then, platelet-rich
plasma was collected and centrifuged at 1000 g for 15 min at 4C.
Next, plasma sample without any pelleted cells was collected and stored
at -80C until analysis. Samples were analysed for IFN-c, IL-1b, IL-6, IL-
10, IL-17A, IL-17E, IL-23, IL-33, MIP-3a/CCL20, and TNF-a with Luminex
technology using standard kits with magnetic beads (MILLIPLEX MAP
Human TH17 Panel—Immunology Multiplex Assay HTH17MAG-14K,
Millipore, Merck) and were read on a Luminex 200 machine (Biorad) in
accordance with the manufacturer’s instructions.
Statistical analysis
Analyses were performed with SPSS (ver. 25.0) statistical package unless
otherwise stated. MR analysis was performed using MR-PRESSO
(Mendelian Randomization Pleiotropy RESidual Sum and Outlier).26
Additional causal estimation analyses were performed using inverse-vari-
ance weighted, and simple median-based methods using
MendelianRandomization package in R (ver. 3.5.1).27
Based on previous evidence, the clinical study was powered (80%)
with a sample of 50 participants per group to detect a 7 mmHg difference
in BP between study groups and a 13 mmHg standard deviation of the
change in SBP.28–31 All the analyses were performed based on the
intention-to-treat principle, per-protocol analyses for the outcomes
reported are included. Means and 95% confidence intervals (95% CIs) of
continuous variables are presented according to treatment groups.
Categorical variables count and percentages are presented according to
the treatment group and values were tested using the v2 test. In the dis-
covery analyses, cytokines and cell types were compared using the paired
t-test for each of the treatment groups separately. Between group differ-
ences and differences from baseline to 2-month of follow-up were tested
with the use of repeated-measures analysis of variance (ANOVA) with
interaction term between group and time defined by two visits. We used
one-sided tests for analysis of cytokines and cell types based on hypoth-
esis from previous studies.28 Correlation analyses between the BP out-
comes and changes in dental parameters were performed using
Spearman Rank tests. Mediation analysis was performed using mediation
package in R32,33 and tested average causal mediation effect of treatment
group on change in SBP that is due to the change in periodontal pocket
depth (PPD). P-values <0.05 were considered significant.
......................................... ......................................... ................................................................
....................................................................................................................................................................................................................
Table 1 Results of Mendelian randomization analysis in the combined UK Biobank and International Consortium of
Blood Pressure–Genome-Wide Association Studies populations
Phenotype MR-PRESSO Median IVW (inverse-variance weighted)
Causal
estimate
SD P Causal
estimate
SE P Causal
estimate
SE P
Systolic blood pressure (SBP) 0.177 0.014 0.001 0.177 0.084 0.036 0.177 0.072 0.013
Diastolic blood pressure (DBP) 0.069 0.012 0.011 0.076 0.048 0.114 0.069 0.041 0.093
Pulse pressure (PP) 0.110 0.015 0.005 0.115 0.057 0.044 0.110 0.049 0.023
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Mendelian randomization links
hypertension to periodontitis
Mendelian randomization utilizes genetic variants that serve as proxy
measures for modifiable risk factors to allow estimation of the causal
influence of the modifiable risk factor in question. We, therefore,
used four SNPs, in LOC107984137, MTND1P5, DEFA1A3, and
SIGLEC5 loci, previously associated with periodontitis in GWAS, as
instruments for making causal inferences about the role of periodon-
titis in human BP regulation. All studied SNPs showed concordant ef-
fect direction i.e. the same allele was associated with both increased
....................................................................................................................................................................................................................
Table 2 Baseline characteristics of the study population
Control periodontal
treatment (CPT; n5 51)
Intensive periodontal
treatment (IPT; n5 50)
Age (years) 56 (54–58) 53 (50–56)
Sex, n (%)
Male 31 (60) 26 (52)
Female 20 (40) 24 (48)
BMI 29 (28.1–30.7) 28 (26.8–29.2)
Smoking, n (%)
Never 26 (51) 26 (51)
Current 15 (29) 17 (34)
Past 10 (20) 7 (14)
Diabetes mellitus, n (%)
Type 1 0 0
Type 2/glucose intolerance 6 (11) 4 (8)
Office SBP (mmHg) 154 (150.6–158.9) 155 (152.4–158.5)
Office DBP (mmHg) 89 (85–92) 92 (89–95)
Ambulatory 24 h BP
Average SBP (mmHg) 132 (127–136) 135 (130–138)
Average DBP (mmHg) 80 (77–82) 84 (80–86)
Heart rate (b.p.m.) 72 (69–74) 72 (69–75)
Activity SBP (mmHg) 136 (131–140) 138 (135–142)
Activity DBP (mmHg) 83 (80–86) 87 (85–90)
Night SBP (mmHg) 119 (114–124) 121 (117–126)
Night DBP (mmHg) 70 (67–73) 71 (68–74)
Total cholesterol (mmol/L) 5.3 (5.0–5.6) 5.8 (5.5–6.1)
TG (mmol/L) 1.8 (1.5–2.2) 1.7 (1.5–2.0)
LDL cholesterol (mmol/L) 3.2 (2.9–3.4) 3.6 (3.4–3.9)
HDL cholesterol (mmol/L) 1.3 (1.2–1.4) 1.4 (1.3–1.5)
Creatinine (mmol/L) 92 (89.1–96.7) 88 (84.2–91.5)
Fasting Glucose (mmol/L) 5.7 (5.5–6.1) 5.4 (5.2–5.7)
White blood cells (1000/mm3)a 6.7 (6.1–7.3) 6.1 (5.7–6.5)
Mean periodontal probing depth (mm) 2.9 (2.8–3.1) 2.9 (2.8–3.1)
Mean CAL (mm) 3.7 (3.4–4.0) 3.8 (3.5–4.1)
Mean CIPTN 3.2 (3.1–3.4) 3.1 (2.9–3.3)
Number of teeth 21 (18.7–22) 22 (19.7–23.1)
Number of anti-hypertensives 2.2 (1.8–2.5) 2.1 (1.8–2.4)
Beta-blocker, n (%) 22 (43) 20 (40)
Calcium channel blocker, n (%) 19 (37) 16 (32)
ACR-I/ARB, n (%) 38 (75) 37 (74)
Alpha-blocker, n (%) 4 (8) 4 (8)
Diuretic, n (%) 29 (56) 26 (52)
HMG-CoA inhibitors, n (%) 16 (31) 13 (26)
aData are averages with 95% CI or patient numbers with percentages in brackets. All differences in characteristics between groups were non-significant.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; BMI, body mass index; CAL, clinical attachment loss; CIPTN, community periodontal index of treat-
ment needs; HMG-CoA, b-hydroxy b-methylglutaryl-coenzyme A; TG, triglycerides.
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risk for periodontitis and increased level of BP index (Supplementary
material online, Table S1 and Figure S1). MR-PRESSO analysis did not
identify significant horizontal pleiotropic variants and demonstrated a
significant effect of periodontitis on all three BP indexes. Median-
based and inverse-variance weighted approaches detected nominally
significant causal association between periodontitis-linked SNPs and
SBP or PP (Table 1).
Clinical study
About 101 consecutive patients were randomized to IPT or CPT
control group between 10 December 2009 and 5 January 2015.
Whilst office BP of all patients exceeded 140/90 mmHg in all partici-
pants, the whole group active period ABPM was 137± 15/
86± 10 mmHg. Both study groups did not significantly differ in any of
the medical or dental characteristics at baseline (Table 2). Fifty
patients were assigned to IPT, while 51 were assigned to control
treatment (Figure 1). Notably, in both groups, five patients did not
reach the 2-month time point and were lost to follow-up (Figure 1).
No serious adverse events were reported.
Effects of periodontal treatment on
blood pressure
Intensive periodontal treatment caused a significant reduction of
average 24-h SBP (Figure 2A) as well as DBP (Figure 2B) by 7.5 and
5.8 mmHg, respectively. Interestingly, in the control treatment group
a borderline significant increases of BP values were observed, leading
to the difference in change of SBP of 11.1 mmHg (95% CI 6.5–15.8)
and DBP of 8.3 mmHg (95% CI 3.98–12.6) between CPT and IPT
groups (Figure 2A and B). These changes in BP were not accompanied
by any change in average daily heart rate (72 ± 10 vs. 71.6 ± 9 b.p.m.;
P= 0.3). We also analysed anti-hypertensive effect of IPT in relation
to baseline BP showing, as expected, that the degree of SBP reduc-
tion was dependent on baseline SBP value (Figure 2C). Significant sys-
tolic, diastolic, and PP reductions were observed both in daytime
(activity) and during the nighttime (Supplementary material online,
Table S2). We have also performed a subgroup analysis to determine
if any of patient subgroups benefited the most. While no difference
was observed depending on sex, initial periodontal status, or number
of anti-hypertensive medications, a significant effect (P-value for inter-
action < 0.05) was evident for age and borderline effect for body
mass index, indicating that periodontitis might have stronger link to
hypertension in younger individuals. (Supplementary material online,
Figure S3).
Effects of periodontal treatment on
vascular function
Intensive periodontal treatment participants presented with
increased FMD at 2 months after therapy compared to CPT [differ-
ence of -1.72% (95% CI -3.1 to -0.4); P< 0.01; Supplementary mater-
ial online, Figure S2A]. Non-endothelium dependent, nitroglycerine-
induced vasodilatation did not change between study groups
(Supplementary material online, Figure S2B).
Figure 1 A flowchart of clinical study profile.
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Dental status changes
Intensive periodontal treatment produced a substantial improve-
ment in periodontal health of all participants when compared to
CPT patients [periodontal probing pocket depth difference of
0.55 mm, 95% CI 0.38–0.72, P< 0.001; Figure 3A]. Similar differen-
ces were observed in average periodontal clinical attachment level
(Figure 3B). Notably, the degree of individual BP change at
2 months was positively correlated with the change of periodontal
probing depth (Figure 3C) in the IPT group. This correlation
remained statistically significant after correction for the baseline
SBP value (Rs = 0.34; P< 0.05) or when all studied participants
were taken into account (Rs = 0.46; P< 0.001). Moreover, to test
whether changes in periodontal status mediate the benefits of IPT
on BP we performed mediation analysis. This demonstrated a sig-
nificant average direct effect of treatment group on change in SBP
[estimate = 8.92 (95% CI 3.68–14.29), P= 0.001] and a significant
average causal mediation effect of treatment group on change in
SBP that is due to change in PPD [estimate = 3.59 (95% CI 0.52–
7.10), P= 0.021; proportion of total effect due to mediation =
0.29 (95% CI 0.04–0.61), P= 0.021].
Figure 2 Effects of conventional periodontal treatment and intensive periodontal treatment on blood pressure. Changes of 24-h average systolic
(A) and diastolic (B) blood pressure between baseline and 2 months following control periodontal treatment or intensive periodontal treatment are
reported as mean ± 95% confidence interval. Subsequently, difference in change was calculated between randomization groups. (C) Relationship be-
tween baseline systolic blood pressure and the effect of intensive periodontal treatment on blood pressure reduction. Patients were divided in ter-
tiles of baseline ambulatory 24-h blood pressure monitoring measured systolic blood pressure and change of systolic blood pressure between
baseline and follow-up (delta systolic blood pressure) was analysed and presented as mean with 95% confidence interval. Ambulatory 24-h blood
pressure monitoring Tertile 1: <130 mmHg; Tertile 2: 131–138 mmHg; and Tertile 3 >138 mmHg.
6 M. Czesnikiewicz-Guzik et al.
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mediators
Luminex analyses confirmed that IPT produced modest but statis-
tically significant reductions in plasma levels of IL-6, IFN-c, IL-17A,
and TNF-a (Table 3). The differences remained significant in
ANOVA only in relation to IFN-c (CPT change: -2.2 ± 4.7, IPT
change: -12.6 ± 2.8); difference in change: 10.4 pg/mL and IL-6
(CPT change: 0.3± 2.4, IPT change: -5.7 ± 2.2); difference in
changes: 6.0 pg/mL. No differences were noted in the other circu-
lating biomarkers.
Whilst no changes in pro-inflammatory monocytes or CD4þ T
cells were observed in IPT, we observed a substantial reduction of
activated CD8 cells characterized by expression of CD38þ cells in
the IPT but not CPT group (Figure 4). This reduction remained statis-
tically significant after correction for multiple comparisons (FDR) and
in two-way ANOVA analyses [CPT change: 0.56 ± 1.27, IPT change:
-4.60 ± 1.39; difference in changes: 5.16 (95% CI 1.39–8.93), Figure 4].
Moreover, a reduction in circulating immunosenescent CD8þ
CD28nullCD57þ cells between study groups was observed in IPT
but not CPT group (Figure 4A–C).
Figure 3 Effects of control periodontal treatment and intensive periodontal treatment on periodontal status and its relationship to blood pressure
improvement. Changes of periodontal pocket depth (A) and clinical attachment loss (B) were monitored between baseline and 2 months following
control periodontal treatment or intensive periodontal treatment and are reported as mean ± 95% confidence interval along with difference in
change calculated between randomization groups (with 95% confidence interval). (C) Spearman correlation between improvement of systolic blood
pressure and change of periodontal pocket depth in individual patients.
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Discussion
In the present study, we report evidence of a causal relationship be-
tween periodontitis and hypertension using two complementary and
independent research methods. Firstly a two-sample MR approach
using a large sample population (750 000 participants) and non-
palindromic SNPs analysis linking loci that were previously GWAS-
associated to periodontitis with hypertension. The association be-
tween periodontitis and hypertension was also supported by a
randomized controlled trial of non-surgical periodontal therapy.
Improvement of periodontal status, following IPT, was directly
related to the 24-h BP profile improvement. These effects on BP
were accompanied by reduction of systemic pro-hypertensive cyto-
kine levels ([IFN-c, IL-6, IL-17A, and TNF-a), as well as activated
(CD38þ) and immunosenescent dysregulated CD57þ/CD28null
CD8þ T cells, that were previously linked to hypertension.34
This is the first study using a two-sample MR to gain inferences
about a causal relationship between periodontitis and BP indexes.
While recent publications of GWAS studies have helped in identify-
ing possible genetic tools,15,16 a low number of available instrumental
variables remains a limitation of this approach. Depending on the cal-
culation method, heritability estimates of periodontitis are highly vari-
able and included instrumental variables likely explain small
proportion of genetic background of periodontitis.35 Nevertheless, it
did allow for successful identification of the links between
periodontitis-linked SNPs and systolic, diastolic, and PP using a num-
ber of independent Mendelian randomization approaches. This indi-
cates that in the future, this genetic instrument can be very valuable
to address the link between periodontitis and hard cardiovascular
endpoints.
In the studies used to generate the Mendelian randomization
results, information on hard cardiovascular outcomes are available.
This is important as the link between periodontitis and risk cardiovas-
cular disease remains a topic of extreme interest. Genetic tool used
in this study, can be useful in future investigations of hard cardiovas-
cular endpoints.
To the best of our knowledge, our work is the first attempt to ad-
dress the question of whether non-surgical periodontal treatment
can reduce BP in hypertensive patients with ambulatory 24-h BP
monitoring as the primary outcome. The use of 24-h ABPM as a pri-
mary endpoint in our study is of particular importance for consist-
ency and validity of results in modestly sized trials.36 Out of a total of
12 interventional studies performed to date in patients with peri-
odontitis that have reported BP values, only one addressed the ques-
tion of BP reduction as a primary outcome,12 however, this involved
patients with high normal BP rather than those with hypertension.
Zhou et al.37 reported an absolute difference of office SBP of
12.57 mmHg, 95% CI 10.45–14.69, P< 0.05 between treatment arms.
In majority of other interventional studies of sufficient size, including
our recent clinical trials, where BP was reported, uncontrolled hyper-
tension was an exclusion criterion.10,28
In our study, IPT was associated with a 7.5 ± 10 mmHg reduction
of BP. This could represent an important health change linked to pre-
vention of hypertension complications. A recent meta-analysis of
hypertensive randomized clinical trials reported that a 10-mmHg re-
duction in systolic and/or 5-mmHg reduction in DBP resulted in a
25–30% reduction of cardiovascular events including stroke and
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Figure 4 Effects of control periodontal treatment and intensive periodontal treatment on selected T lymphocyte and monocyte populations. (A)
Heatmap presenting 23 cell subpopulations with ratio of baseline- and post-treatment levels between control periodontal treatment and intensive
periodontal treatment patients. Cell types were selected on the basis of previous reports of significance for hypertension and vascular regulation.
Colour of each square corresponds to a baseline and follow-up (2 months) means for intensive periodontal treatment and control periodontal treat-
ment groups of each analysed cell type. Differences in absolute values that were significant (P< 0.05) after FDR correction in intensive periodontal
treatment but not control periodontal treatment in our discovery analysis are marked with asterisk. Heatmap was generated using ClustVis software.
Examples of flow cytometry (B) and average values (C) detecting cell types of activated (CD38) and immunosenescent (CD28null, CD57þ) CD8þT
cells between baseline and 2 months post-treatment in control periodontal treatment and intensive periodontal treatment groups. *P< 0.05 vs. base-
line; two-way analysis of variance.
Causal relationship between periodontitis and hypertension 9
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehz646/5556904 by U
niversity of G
lasgow
 user on 11 Septem
ber 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
heart failure.38 Our results are consistent with recent large cross-
sectional NHANES survey of 11 753 participants that showed that
good periodontal health is associated with better SBP profile during
anti-hypertensive therapy by about 2.3–3 mmHg and with lower
odds of anti-hypertensive treatment failure.39
In this study, we observed improvements in endothelial function
after periodontal therapy. As endothelial function is one of the key
mechanisms for vascular risk in hypertension, our observations link-
ing it to periodontal inflammation is of primary importance. This is
consistent with the previous observations that periodontitis is associ-
ated with endothelial dysfunction and that the latter is improved by
IPT.10 More importantly, such improvement, in hypertensive patients
was already observed 2 months after IPT, earlier than in other cardio-
vascular risk populations.10 We have not measured pulse wave vel-
ocity or vascular stiffness, as our follow-up period was likely too
short to observe significant change. In future, longer, studies it may
represent a valuable outcome providing additional insights into vascu-
lar biology of periodontitis.
Periodontitis is associated with systemic inflammation evidenced
by high C-reactive protein/high asymmetric dimethylarginine levels,40
as well as circulating cytokines and adipokines.28 In addition, as white
blood cell counts have been linked to periodontitis,41 we also investi-
gated cellular signature of inflammation. Reductions of circulating
activated and dysregulated CD8 cells of immunosenescent pheno-
type observed in this study are of interest,42 as patients with
hypertension show an increased presence of immunosenescent, pro-
inflammatory, cytotoxic CD8þ T cells characterized by presence of
CD57þ and lack of CD28 (CD28null).34 Interestingly these cells are
an important source of TNF-a and IFN-c and they have been shown
to infiltrate kidneys and vessels in hypertensive patients, through
which they can contribute to development of the disease. Moreover,
we have also recently demonstrated that these cells
(CD57_CD28null) are first to be recruited to sites of vascular injury
in humans which makes them particularly important from the per-
spective of vascular function regulation.25 However number of condi-
tions can affect development of these immunosenescent cells34 and,
while interesting, extent of changes observed here was modest, and
does not prove their causal role linking periodontitis to hypertension.
While we have measured a number of pro-and anti-inflammatory
cytokines, particularly notable reductions were observed in pro-
inflammatory cytokines which have been shown to contribute to
hypertension by previous studies. This includes TNF-a,43 IFN-c,44 IL-
17A,45 and IL-6.46 In particular, IFN-c has been associated with vascu-
lar and BP phenotypes.34,44,47,48
Interestingly, these systemic changes were observed in our
patients who were characterized by moderate to severe level of peri-
odontitis. Notably, average whole mouth periodontal probing depth
was lower than in some of the previous trials which recruited patients
with more severe forms of periodontitis. This was likely linked to our
model of patient ascertainment from general medical practices rather
than solely periodontal clinics. We have clearly observed that in such
patients, even after a single treatment visit periodontal status remains
improved after 2 months with reduction of systemic inflammatory
markers. In longer-term observations, the effects of initial therapy are
often obscured by poor adherence of patients regarding domiciliary
dental hygiene routines. Our study represents a unique proof-of-
concept which could well serve for the design of a larger, multi-
centre and longer follow-up trial.
One of the surprising observations of the current study was an in-
crease of ABPM BP in control treatment patients during the follow-
up. This is consistent with recent observation in a high normal BP
group of patients.37 At 2 months following conventional treatment,
we did not observe significant changes of inflammatory cytokines.
Other factors linked to continued periodontitis could also contribute
to worsening of BP control in this group of patients. Such change
could be related to worse treatment adherence in this group of
patients, although it is important to note that we studied patients
with long-term chronic hypertension who have already used stable
treatment before inclusion into the study.
Limitations
Our clinical study should be considered as proof of concept and
needs to be confirmed in a large cohort of hypertensive patients.
Firstly, the population included in the trial cannot be considered as
having resistant hypertension, but simply as an insufficiently con-
trolled BP. In order to ensure that changes of treatment will not be a
major cause for BP alterations, patients who required a change of
anti-hypertensive therapy during the trial were excluded. While in a
2-month time of follow-up this was a rare event, it might be an im-
portant consideration for future long-term studies, as may either
preferentially exclude or include patients particularly prone to inflam-
matory mechanism. In line with this, effects of periodontal therapy on
medication adherence need to be carefully monitored as it is highly
important for addressing the effect of diverse therapies on BP out-
comes. Similarly, while number of patients studied was sufficient to
show effects on primary outcome, inclusion of more participants
would have strengthened the study results given the variability of the
response to therapy. While our study provides valuable proof of con-
cept, a longer follow-up of 6 or 12 months would be needed to allow
for therapeutic recommendations and conclusions. Finally, while not
significant, the intensive treatment group compared to standard
treatment was characterized by numerically higher 24-h blood pres-
sure. While this difference is not significant, we have to remain cau-
tious that it might have affected BP outcome.
In conclusion, the present study supports a causal relationship be-
tween periodontitis and hypertension. While the mechanisms of this
relationship warrant further investigation, we have provided genetic
and experimental evidence that periodontitis is linked to hyperten-
sion. These preliminary results need to be confirmed in a large cohort
of hypertensive patients as they may represent a novel non-
pharmacological intervention for the management of hypertension.
Supplementary material
Supplementary material is available at European Heart Journal online.
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